Literature DB >> 19268462

Galectin-8 interacts with podoplanin and modulates lymphatic endothelial cell functions.

Leah N Cueni1, Michael Detmar.   

Abstract

Podoplanin is a small, mucin-like membrane glycoprotein highly expressed by lymphatic but not by blood vascular endothelial cells. Although it was shown to be indispensable for the correct formation and function of the lymphatic vasculature, its precise molecular function has remained unknown. In the present study, we identified the mammalian lectin galectin-8 as a novel, glycosylation-dependent interaction partner of podoplanin. Galectin-8 is a tandem-repeat type galectin, which interacts with cell surface glycoproteins, including certain integrins, as well as with extracellular matrix molecules such as fibronectin. Here we show that, similar to podoplanin, galectin-8 is more highly expressed by lymphatic than by blood vascular endothelial cells, and that it promotes lymphatic endothelial cell adhesion as well as haptotactic migration when immobilized onto a surface, while inhibiting the formation of tube-like structures by lymphatic endothelial cells in a collagen matrix when incorporated into the matrix. Importantly, functions of blood vascular endothelial cells, which lack podoplanin expression, are not affected by galectin-8. These data suggest a role for galectin-8 and podoplanin in supporting the connection of the lymphatic endothelium to the surrounding extracellular matrix, most likely in cooperation with other glycoproteins on the surface of lymphatic endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19268462      PMCID: PMC3398156          DOI: 10.1016/j.yexcr.2009.02.021

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  27 in total

Review 1.  Lectin-resistant CHO glycosylation mutants.

Authors:  Santosh Kumar Patnaik; Pamela Stanley
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

2.  Functional glycosylation of human podoplanin: glycan structure of platelet aggregation-inducing factor.

Authors:  Mika Kato Kaneko; Yukinari Kato; Akihiko Kameyama; Hiromi Ito; Atsushi Kuno; Jun Hirabayashi; Tomomi Kubota; Koh Amano; Yasunori Chiba; Yasushi Hasegawa; Isoji Sasagawa; Kazuhiko Mishima; Hisashi Narimatsu
Journal:  FEBS Lett       Date:  2007-01-11       Impact factor: 4.124

3.  The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells.

Authors:  Victor L Thijssen; Sarah Hulsmans; Arjan W Griffioen
Journal:  Am J Pathol       Date:  2008-01-17       Impact factor: 4.307

4.  Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition.

Authors:  Ester Martín-Villar; Diego Megías; Susanna Castel; Maria Marta Yurrita; Senén Vilaró; Miguel Quintanilla
Journal:  J Cell Sci       Date:  2006-10-17       Impact factor: 5.285

5.  Affinity of galectin-8 and its carbohydrate recognition domains for ligands in solution and at the cell surface.

Authors:  Susanne Carlsson; Christopher T Oberg; Michael C Carlsson; Anders Sundin; Ulf J Nilsson; David Smith; Richard D Cummings; Jenny Almkvist; Anna Karlsson; Hakon Leffler
Journal:  Glycobiology       Date:  2007-03-05       Impact factor: 4.313

6.  Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas.

Authors:  Ester Martín-Villar; Francisco G Scholl; Carlos Gamallo; Maria M Yurrita; Mario Muñoz-Guerra; Jesús Cruces; Miguel Quintanilla
Journal:  Int J Cancer       Date:  2005-03-01       Impact factor: 7.396

7.  Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors.

Authors:  Vivien Schacht; Soheil S Dadras; Louise A Johnson; David G Jackson; Young-Kwon Hong; Michael Detmar
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

Review 8.  Galectins in the tumor endothelium: opportunities for combined cancer therapy.

Authors:  Victor L J L Thijssen; Françoise Poirier; Linda G Baum; Arjan W Griffioen
Journal:  Blood       Date:  2007-06-25       Impact factor: 22.113

9.  Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells.

Authors:  Katsue Suzuki-Inoue; Yukinari Kato; Osamu Inoue; Mika Kato Kaneko; Kazuhiko Mishima; Yutaka Yatomi; Yasuo Yamazaki; Hisashi Narimatsu; Yukio Ozaki
Journal:  J Biol Chem       Date:  2007-07-06       Impact factor: 5.157

10.  Identification of PA2.26 antigen as a novel cell-surface mucin-type glycoprotein that induces plasma membrane extensions and increased motility in keratinocytes.

Authors:  F G Scholl; C Gamallo; S Vilaró; M Quintanilla
Journal:  J Cell Sci       Date:  1999-12       Impact factor: 5.285

View more
  33 in total

Review 1.  Galectins in tumor angiogenesis.

Authors:  Arjan W Griffioen; Victor L Thijssen
Journal:  Ann Transl Med       Date:  2014-09

Review 2.  Role of galectins in re-epithelialization of wounds.

Authors:  Noorjahan Panjwani
Journal:  Ann Transl Med       Date:  2014-09

3.  Inflammation-induced lymphatic architecture and bone turnover changes are ameliorated by irisin treatment in chronic inflammatory bowel disease.

Authors:  S Anand Narayanan; Corinne E Metzger; Susan A Bloomfield; David C Zawieja
Journal:  FASEB J       Date:  2018-03-29       Impact factor: 5.191

4.  Mutation of threonine 34 in mouse podoplanin-Fc reduces CLEC-2 binding and toxicity in vivo while retaining antilymphangiogenic activity.

Authors:  Roberta Bianchi; Eliane Fischer; Don Yuen; Ellen Ernst; Alexandra M Ochsenbein; Lu Chen; Vivianne I Otto; Michael Detmar
Journal:  J Biol Chem       Date:  2014-07-25       Impact factor: 5.157

Review 5.  Development of the endothelium: an emphasis on heterogeneity.

Authors:  Laura A Dyer; Cam Patterson
Journal:  Semin Thromb Hemost       Date:  2010-05-20       Impact factor: 4.180

6.  Podoplanin negatively regulates CD4+ effector T cell responses.

Authors:  Anneli Peters; Patrick R Burkett; Raymond A Sobel; Christopher D Buckley; Steve P Watson; Estelle Bettelli; Vijay K Kuchroo
Journal:  J Clin Invest       Date:  2014-11-21       Impact factor: 14.808

7.  PKA and CDK5 can phosphorylate specific serines on the intracellular domain of podoplanin (PDPN) to inhibit cell motility.

Authors:  Harini Krishnan; Edward P Retzbach; Maria I Ramirez; Tong Liu; Hong Li; W Todd Miller; Gary S Goldberg
Journal:  Exp Cell Res       Date:  2015-05-07       Impact factor: 3.905

8.  Podoplanin-Fc reduces lymphatic vessel formation in vitro and in vivo and causes disseminated intravascular coagulation when transgenically expressed in the skin.

Authors:  Leah N Cueni; Lu Chen; Hui Zhang; Daniela Marino; Reto Huggenberger; Annamari Alitalo; Roberta Bianchi; Michael Detmar
Journal:  Blood       Date:  2010-08-17       Impact factor: 22.113

Review 9.  Podoplanin - a small glycoprotein with many faces.

Authors:  Maciej Ugorski; Piotr Dziegiel; Jaroslaw Suchanski
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

10.  A newly generated functional antibody identifies Tn antigen as a novel determinant in the cancer cell-lymphatic endothelium interaction.

Authors:  Carla Danussi; Anna Coslovi; Cristiana Campa; Maria T Mucignat; Paola Spessotto; Fulvio Uggeri; Sergio Paoletti; Alfonso Colombatti
Journal:  Glycobiology       Date:  2009-06-15       Impact factor: 4.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.